Peptide News Forum

ARA-290

ARA-290 (also known as cibinetide) is a synthetic 11-amino acid peptide. It is engineered from the tissue-protective structure of erythropoietin (EPO), but it is modified to remove the ability to produce red blood cells.

Key Benefits

  • Supports nerve repair and regeneration processes in research settings
  • Helps reduce neuropathic pain signaling in damaged nerve models
  • Supports reduction of inflammation in injured or stressed tissues
  • Promotes recovery in Small Fiber Neuropathy research studies
  • Helps protect nerves from ongoing cellular damage
  • Supports tissue healing in ischemia-related injury models
  • May improve corneal and peripheral nerve fiber health in studies
  • Promotes overall regenerative and anti-inflammatory repair pathways
Order Now

Uses

  • Supports research into nerve repair and regeneration
  • Studied for treatment of neuropathic pain conditions
  • Investigated for Small Fiber Neuropathy (SFN), especially in diabetes and sarcoidosis
  • Explored for reducing inflammation in damaged tissues
  • Used in research on ischemia (reduced blood flow injury)
  • Supports studies on cellular protection and tissue recovery
  • Investigated for protecting nerves from chronic damage
  • Used in experimental regenerative medicine trials

Trade Names in USA and Manufacturers

  • ARA-290 has no FDA-approved brand names
  • It is not available as a prescription medication
  • Originally developed under the name Cibinetide
  • Developed by Araim Pharmaceuticals (historical developer)
  • Now mainly produced by research peptide suppliers such as:
    • Peptide Sciences
    • Verified Peptides
    • Core Peptides
  • Sold strictly as a research compound

Dosage

  • No FDA-approved dosage exists
  • Human dosing is based on limited clinical research
  • Common trial-based protocol includes:
    • 4 mg once daily
  • Administered via subcutaneous injection
  • Typical cycle duration:
    • Around 28 days in research studies
  • Lower-dose experimental protocols also exist
  • Dosing varies depending on research goals

Pricing

  • Considered a premium research peptide
  • A vial typically contains 12 mg to 16 mg
  • Price range is approximately:
    • $65 to $110 per vial
  • Monthly research cycles may cost:
    • $200 to $400
  • Cost depends on supplier and purity level
  • Higher doses increase total protocol cost

Coverage by Insurance Type

  • Not covered by any health insurance plan
  • This includes:
    • Private insurance
    • Medicare
    • Medicaid
  • Classified as an experimental compound
  • Patients or researchers pay 100% out of pocket
  • No reimbursement options are available

Tips

  • Reconstitute using sterile bacteriostatic water
  • Store in a refrigerator at 2°C to 8°C
  • Avoid exposure to heat and light
  • Use sterile injection technique
  • Only buy from suppliers with third-party HPLC testing
  • Ensure purity is 98% or higher when available
  • Handle carefully to maintain peptide stability

Side Effects

  • Mild injection site irritation
  • Redness or bruising
  • Temporary burning sensation at injection site
  • Mild headaches in some users
  • Occasional nausea
  • Temporary lightheadedness
  • Generally well tolerated in short-term studies
  • Long-term effects are not fully known

Contraindications

  • Do not use if allergic to erythropoietin-related compounds
  • Avoid in individuals with active cancer
  • Not recommended for pregnant women
  • Not recommended for breastfeeding women
  • Avoid in individuals with severe immune-related conditions
  • Use only under medical supervision in high-risk cases
  • Safety data is still limited

Pharmacology

  • ARA-290 is a synthetic 11-amino acid peptide
  • Derived from the erythropoietin (EPO) structure
  • Designed to avoid red blood cell production effects
  • Does not increase hematocrit or blood viscosity
  • Targets tissue protection pathways instead of blood formation
  • Focuses on nerve and tissue repair signaling pathways
  • Classified as a non-erythropoietic peptide analog

Mechanism of Action

  • Binds to the Innate Repair Receptor (IRR)
  • IRR includes the erythropoietin receptor and CD131 receptor
  • Activates anti-inflammatory signaling pathways
  • Reduces cytokines like TNF-alpha and IL-1 beta
  • Suppresses overactive immune responses in damaged tissue
  • Supports nerve fiber repair and regeneration
  • Helps reduce cell death (apoptosis) in injured tissues
  • Promotes healing in nerve and vascular injury models

Result Claims by Different Companies

  • Claimed to reduce chronic nerve pain
  • Marketed for neuropathy symptom relief
  • Promoted for nerve regeneration support
  • Claimed to restore small nerve fiber density
  • Marketed for metabolic and glucose-related benefits
  • Claimed to protect tissues from ischemic damage
  • Results are based mainly on early research and clinical trials
  • Not confirmed in large-scale FDA-approved studies